Survival benefit of postoperative radioiodine therapy among patients with intermediate-risk differentiated thyroid carcinoma.

MLA

Wang, Jinwen, et al. “Survival Benefit of Postoperative Radioiodine Therapy among Patients with Intermediate-Risk Differentiated Thyroid Carcinoma.” Endocrine (1355008X), vol. 86, no. 2, Nov. 2024, pp. 664–71. EBSCOhost, https://doi.org/10.1007/s12020-024-03869-2.

APA

Wang, J., Mao, Y., Li, L., Liang, J., Huang, H., Lin, W., Chen, G., & Wen, J. (2024). Survival benefit of postoperative radioiodine therapy among patients with intermediate-risk differentiated thyroid carcinoma. Endocrine (1355008X), 86(2), 664–671. https://doi.org/10.1007/s12020-024-03869-2

Chicago

Wang, Jinwen, Yaqian Mao, Liantao Li, Jixing Liang, Huibin Huang, Wei Lin, Gang Chen, and Junping Wen. 2024. “Survival Benefit of Postoperative Radioiodine Therapy among Patients with Intermediate-Risk Differentiated Thyroid Carcinoma.” Endocrine (1355008X) 86 (2): 664–71. doi:10.1007/s12020-024-03869-2.